Asia TIDES®– Oligonucleotide and Peptide 2012

Venue: Sheraton Miyako Tokyo

Location: Tokyo, Japan

Event Date/Time: Feb 28, 2012 End Date/Time: Mar 01, 2012
Report as Spam


AsiaTIDES continues to be the premier forum to get a comprehensive update, meet key players and increase your knowledge of the oligonucleotide- and peptide-based therapeutics fields.

The faculty list for the 2012 program is the strongest yet, with more representation from big pharma than ever before. Hear new data and strategic perspectives from Merck, Genzyme, and GlaxoSmithKline, including three presentations from Glaxo on a peptide project and their assessments of both the oligo and peptide landscape. Plus hear from Isis, Novo Nordisk, Ipsen, Quark, Alnylam, Santaris, Tekmira and a host of other important companies you need to follow to stay abreast of this field.


Additional Information

Keynote Presentations Clinical Development of Mipomersen, an Antisense Second-Generation Oligonucleotide Targeting Apolipoprotein B Tejdip Singh, M.D. Medical Director, Global Patient Safety and Risk Management, Genzyme Corporation, USA Oligonucleotide and Delivery Platform Optimization Strategies for siRNA Drug Development Laura Sepp-Lorenzino, Ph.D. Senior Director, RNA Therapeutics, Merck & Co., Inc., USA Recent Advances in Routes of Delivery for Peptide Pharmaceuticals Nozer Mehta, Ph.D. Vice President, R&D, UniGene Laboratories, Inc., USA Overview of Peptide Therapeutics and Vaccines in Development Yuji Heike, M.D., Ph.D. Hemato-Oncology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Japan Evolution and Development of GLP-1 Based Therapeutics Andrew A. Young, M.D., Ph.D. Vice President, Head, Enterendocrine Biology, GlaxoSmithKline, USA A Pivotal Year for Oligonucleotide Therapeutics Arthur A. Levin, Ph.D. Chief Development Officer, Santaris A/S, USA and Denmark RaPID Selection of a New Class of Peptide Drug Leads against Various Therapeutic Targets Hiroaki Suga, Ph.D. Professor, Chemical Biology and Biotechnology Lab, The University of Tokyo, Japan • Regulatory Updates: Preclinical Safety Assessment of Oligonucleotides and Peptides including Reports from JPMA and the Oligonucleotide Safety Working Group on ICH S6 and Off Target Effects • miRNA, Oligonucleotides, Peptides and Peptide Vaccines: Updates on therapeutic candidates in preclinical and clinical development • Manufacturing and analytical development strategies to speed process development • Formulation and delivery updates to help you gauge product marketability In-Depth Tutorials to Increase your Knowledge: • Technical and Regulatory Aspects of Peptide Specifications and Characterization: From Preclinical through to Market Application • Strategies and Approaches for in vivo Delivery of Oligonucleotides